About WILEX
WILEX AG, a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.
|
|
|
11-50 employees
View all WILEX employees
|
|
Biopharma
|
|
498941313899
|
|
Munich, Bayern
|
|
1997
|
WILEX Alternatives
Frequently Asked Questions about WILEX
Olaf Wilhelm is the CEO of WILEX. To contact Olaf Wilhelm email at [email protected].
The decision makers in WILEX are Alfayaz Sunderji, Burkhard Wilken, Eddie Wilson, etc. Click to Find WILEX decision makers emails.
Search WILEX Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
